2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1808

Exercise Is Associated with Improved Cardiometabolic Risk Factors in Patients with SLE
Abstract Number: 1889

Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Abstract Number: 3001

Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1856

Exosomes from Patients with Active Systemic Lupus Erythematosus Induce a Strong Inflammatory Response
Abstract Number: 1055

Expansions of Salivary Gland CD4+ T Cells from Sjögren’s Syndrome Patients: Single-Cell Repertoire Analysis and Correlation with Clinical Measures of Disease
Abstract Number: 2421

Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Abstract Number: 2437

Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Abstract Number: 124

Experiences with a Structured Questionnaire for Administrative Personnel to Discriminate Urgent and Non-Urgent Rheumatic Patients Referred from Primary to Secondary Care
Abstract Number: 142

Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice
Abstract Number: 78

Exploratory Analysis of Somatic Symptoms in Fibromyalgia By Multidimensional Scaling and Latent Class Analysis
Abstract Number: 2127

Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Subclinical Coronary Atherosclerosis Is Higher Among Rheumatoid Arthritis Patients with the Lowest Circulating Low Density Lipoprotein Concentrations Compared with Controls
Abstract Number: 837

Exposure to ACE Inhibitors Prior to Onset of Scleroderma Renal Crisis Is Not Associated with Increased Risk of Mortality in a Large Retrospective Cohort Study
Abstract Number: 1166

Expression and Function of Proviral Integration Site for Moloney Murine Leukemia Virus 1 (PIM-1) Kinase in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 590

Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient
Abstract Number: 22

Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].